Lexicon Pharmaceuticals, Inc. s in-depth stock price analysis indicates that the stock price has dropped -8.79% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 7.46% . Looking at the past 52 week period, the stock price is up at 72.62% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Lexicon Pharmaceuticals, Inc. has a positive value of 15.73 compared to overall market. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has climbed 6.12% in the past week and advanced 3.46% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 5.26% and the outperformance has advanced to 1.61% for the last 4 weeks period.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) : On Friday heightened volatility was witnessed in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) which led to swings in the share price. The stock opened for trading at $15.05 and hit $15.87 on the upside , eventually ending the session at $15.26, with a gain of 1.8% or 0.27 points. The heightened volatility saw the trading volume jump to 1,034,488 shares. The 52-week high of the share price is $19.62 and the company has a market cap of $1,588 million. The 52-week low of the share price is at $7.65 .
Lexicon Pharmaceuticals Last issued its quarterly earnings results on Nov 1, 2016. The company reported $-0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.16. Analyst had a consensus of $-0.51. The company had revenue of $27.72 million for the quarter, compared to analysts expectations of $11.24 million. The companys revenue was up 4763.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.
Company has reported several Insider transactions to the SEC, on Jun 8, 2016, James F Tessmer (VP, Finance & Accounting) sold 1,500 shares at 15.00 per share price.
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery.